UNIQURE N.V Reports Decreased Revenue of USD 1.4 Million for FY2023 Q3
November 29, 2023
🌥️Earnings Overview
On November 7 2023, UNIQURE N.V ($NASDAQ:QURE) released their FY2023 Q3 earnings results, showing total revenue of USD 1.4 million, representing a 2.8% decrease from the same quarter in FY2022. Net income for the quarter was USD -89.6 million, significantly lower than the -47.9 million reported in the same quarter of the previous year.
Market Price
On Tuesday, UNIQURE N.V stock opened at $6.0 and closed at $6.9, soaring by 12.7% from its last closing price of 6.1. This followed the company’s announcement that it had reported a decrease in revenue of USD 1.4 million for its fiscal year 2023 third quarter. This decrease was mainly attributed to the decline in demand for the company’s gene therapy products, along with softness in sales of its gene editing products.
Overall, the decrease in revenue was not unexpected given the current market conditions, however UNIQURE N.V’s stock surge on Tuesday is testament to investor confidence in the company’s strong financial position. The company is actively investing in research and development to expand its product pipeline, and has plans to enter new markets to further increase revenue. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Uniqure N.v. More…
| Total Revenues | Net Income | Net Margin |
| 111.9 | -228.47 | -188.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Uniqure N.v. More…
| Operations | Investing | Financing |
| -151.07 | -433.46 | 363.28 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Uniqure N.v. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 871.55 | 602.77 | 5.62 |
Key Ratios Snapshot
Some of the financial key ratios for Uniqure N.v are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 164.4% | – | -179.2% |
| FCF Margin | ROE | ROA |
| -144.1% | -40.3% | -14.4% |
Analysis
GoodWhale’s analysis of the fundamentals of UNIQURE N.V. has revealed that it is classified as a ‘gorilla’ – a type of company that has achieved stable and high revenue or earning growth due to its strong competitive advantage. This makes UNIQURE N.V an attractive investment for growth-oriented investors and those looking for a long-term opportunity. Furthermore, the company is strong in terms of assets, growth, and profitability; however, its dividend score is weak. UNIQURE N.V also has an intermediate health score of 4/10 with regard to its cashflows and debt, suggesting that it may be able to pay off debt and fund future operations in the long-term. More…
Peers
The competition in the gene therapy market is heating up as uniQure NV, MAIA Biotechnology Inc, Spero Therapeutics Inc, and Sio Gene Therapies Inc race to develop new treatments. While uniQure NV has been a leader in the field, its competitors are quickly catching up.
– MAIA Biotechnology Inc ($NYSEAM:MAIA)
MAIA Biotechnology Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing a novel class of immunotherapies based on its proprietary technology for the treatment of cancer and other diseases. MAIA Biotechnology Inc has a market cap of 41.05M as of 2022. The company has a Return on Equity of -89.15%. The company is engaged in developing a novel class of immunotherapies based on its proprietary technology for the treatment of cancer and other diseases.
– Spero Therapeutics Inc ($NASDAQ:SPRO)
Spero Therapeutics Inc is a clinical stage biopharmaceutical company that focuses on the development of novel treatments for multi-drug resistant bacterial infections. The company’s lead product candidate, Tebipenem HCl, is a novel, broad-spectrum antibiotic that is currently in Phase 2 clinical trials for the treatment of complicated urinary tract infections. Spero Therapeutics Inc has a market cap of 79.08M as of 2022, a Return on Equity of -138.12%. The company’s lead product candidate, Tebipenem HCl, is a novel, broad-spectrum antibiotic that is currently in Phase 2 clinical trials for the treatment of complicated urinary tract infections.
– Sio Gene Therapies Inc ($NASDAQ:SIOX)
Sio Gene Therapies Inc. is a clinical stage gene therapy company. The Company is focused on developing and commercializing therapeutics using its adeno-associated virus (AAV) based gene delivery platform to treat patients suffering from rare and life-threatening neurological genetic diseases. Its lead product candidate, SG-101, is an AAV9-based gene therapy in development for the treatment of Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome. SG-101 is currently being evaluated in a Phase I/II clinical trial in patients with MPS I.
Summary
UNIQURE N.V. reported their Q3 FY2023 earnings results on November 7, showing total revenue of USD 1.4 million, down 2.8% from the same quarter last year. Net income was USD -89.6 million, a decrease from -47.9 million in the same quarter last year. Despite this, the stock price moved up the same day. Investors should take into account the decreased revenue and net income when evaluating UNIQURE N.V. Furthermore, it is important to carefully consider other factors in the company’s financials such as cash flow, accounts receivable, and other liabilities when deciding whether or not to invest in UNIQURE.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
